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Controlling blood pressure in diabetes is
more important than what agents we use
Diabetic renal insufficiency and failure is 
unfortunately very common, and a significant
cause of death and disability in our patients. We
have been taught from good evidence to start with
ACE inhibitors or ARBs when treating hypertension
in those with diabetes. However, it appears from
this article that controlling blood pressure in dia-
betes is more important than what agents we use.
We often are not aggressive enough in controlling
blood pressure for those with diabetes, despite evi-
dence that it impacts outcomes more than glycemic
control. Though there does not appear to be direct
evidence that other blood pressure agents prevent
renal failure in those with diabetes, it is reassuring
that BP control, even when we are unable to use
ACE inhibitors or ARBs, is a worthy goal.
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Angiotensin-converting enzyme (ACE) inhibitors and
angiotensin-receptor blockers (ARBs) are the first-line
agents for reducing the risk of diabetic nephropathy.
For patients intolerant to these agents, non-dihy-
dropyridine calcium antagonists (NDCAs), such as 
verapamil and diltiazem, are preferred agents to treat
hypertension in those with diabetes who have 
proteinuria (strength of recommendation [SOR]: A,
based on a systematic review). Diuretics are effective
in treating hypertension in patients with diabetes
who are at high risk for cardiovascular disease. One
study suggests sustained-release indapamide (a
diuretic) is effective as first-line treatment in hyper-
tensive patients with diabetes and proteinuria (SOR:
B, based on a randomized controlled trial [RCT]).
Atenolol was as effective as the ACE inhibitor 
captopril in lowering the risk of diabetic microvas-
cular and macrovascular complications, according
to a substudy of the United Kingdom Prospective
Diabetic Study (UKPDS) (SOR: B, based on RCT).
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■ Evidence summary
Diabetic nephropathy is the leading
cause of end-stage renal disease, and it
occurs in 20% to 40% of patients with
diabetes. Optimal glycemic (glycosylated
hemoglobin [HbA1c] level <7%) and
hypertension control (<130/80 mm Hg)
can prevent or slow the progression of
diabetic nephropathy.1–3
An average of 3 antihypertensive
medications are needed to achieve cur-
rently recommended blood pressure
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For those intolerant to ACE inhibitors 
and ARBs, what is the best therapy for
reducing the risk of diabetic nephropathy?
goals in those with diabetes.2 In hyper-
tensive and normotensive patients with
type 2 diabetes and microalbuminuria,
ACE inhibitors have been well studied
and found to reduce the risk of mortality,
major cardiovascular events, and slow
the progression to overt nephropathy, 
in patients with diabetes and at 
least 1 other risk factor.4 In patients with
type 2 diabetes and hypertension,
macroalbuminuria, and serum creatinine
>1.5 mg/dL, ARBs are effective in 
slowing the progression of diabetic
nephropathy.5
Some patients, however, are intoler-
ant to ACE inhibitors and ARBs. When
patients are intolerant to these medica-
tions, diuretics, NDCAs, or beta-blockers
are recommended agents for the treat-
ment of hypertension. 
According to a systematic review,
NDCAs cause a greater reduction in 
proteinuria compared with DCAs 
(dihydropyridine calcium antagonists,
such as nifedipine and amlodipine),
although there was no significant differ-
ences in lowering blood pressure.6 Mean
change in proteinuria was +2% for
DCAs and –30% for NDCAs (95% con-
fidence interval [CI], 10%–54%; P=.01).
In another RCT, amlodipine was no
more effective than placebo in reducing 
proteinuria, while irbesartan effectively
reduced end-stage renal disease (number
needed to treat [NNT]=25 over 2.6
years).5
In the UKPDS-Hypertension in
Diabetes study (a multicenter random-
ized study in patients with type 2 
diabetes that evaluated the effects of 
different levels of blood pressure control
on diabetic complications), researchers
found that patients assigned to the tight-
control group (blood pressure goal
<150/85 mm Hg) had 37% risk reduc-
tion in microvascular endpoints (nephro-
pathy and advanced retinopathy).7 There
was no difference in study endpoints
between the ACE inhibitor captopril and
the beta-blocker atenolol. Selective beta-
blockers like carvedilol appear to have
fewer adverse metabolic effects, although
the clinical significance of this difference
is unclear.8 In insulin-dependent patients
and patients with hypoglycemic episodes,
peripheral vascular disease, and bron-
chospastic disease, beta-blockers should
be used with caution.
The NESTOR study—a multination-
al, multicenter, double-blind, randomized
controlled, 2-parallel-groups study over
1 year—found that indapamide SR (a thi-
azide-type diuretic) treatment is as effica-
cious as enalapril in reducing proteinuria
and lowering blood pressure.9
A meta-analysis of RCTs in patients
with non-diabetic renal disease and RCTs
or time-controlled studies with nonran-
domized crossover design in patients
with diabetic nephropathy revealed that
dietary protein restriction effectively
slows the progression of both diabetic
and non-diabetic renal disease.10 In small
studies, weight loss, use of lipid-lowering
agents, and smoking cessation all
revealed reduction in proteinuria.11,12
Recommendations from others
From the American Diabetes
Association’s “Standards of Medical
Care in Diabetes”12 (position statement):
to reduce the risk or slow the progression
of nephropathy, optimize glucose and
blood pressure control. 
• Patients with diabetes should be
treated to a blood pressure <130/80
mm Hg
• For patients with diabetes and albu-
minuria or nephropathy who are
intolerant to ACE inhibitors or
ARBs, NDCAs, diuretics, or beta
blockers are recommended for treat-
ing hypertension. NDCA use may
reduce albuminuria in patients with
diabetes, including during pregnancy.
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